Pneumonia is the single largest infectious cause of death in children worldwide\nand also a form of an acute respiratory infection that affects the lung.\nThe purpose of the study was to develop a new approach to treat antibiotic-\nresistant K. pneumoniae infection. This study aimed in quest of a drug to\ncombine with ciprofloxacin, a broad spectrum antibiotic frequently used to\ntreat lung infections. Methodology: A total of 23 lung infection bacterial samples\nwere collected and studied against 14 antibiotics of different classes.\nThe disk diffusion method was performed to determine synergy screening,\nMIC value, and qualitative toxicity analysis of ciprofloxacin and chloramphenicol\ncombination. Results: After primary screening of antibiotic susceptibility,\nthey were categorized into multidrug-resistant (MDR), extensively\ndrug-resistant (XDR) and pan drug-resistant (PDR) pathogens where 9 isolates\nwere MDR, 5 were XDR and 3 isolates were PDR. Furthermore, they\nwere trialed in combination ciprofloxacin along with other 7 drugs in disk\ndiffusion to explore the synergistic effect. The combination of ciprofloxacin\nand moxifloxacin, ciprofloxacin and chloramphenicol were found to be synergic.\nThen the MIC test was done for the combination ciprofloxacin and\nchloramphenicol.................................
Loading....